Drug intelligence / Profile preview

RVB-001

Development stage: Preclinical
Lead developer: ResVita Bio
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Cell Therapies, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Topical

Overview

RVB-001 is a genetically engineered probiotic developed by ResVita Bio for the treatment of Netherton syndrome, a rare and life-threatening genetic skin disorder. The therapy consists of non-pathogenic bacteria that are topically applied to the skin, where they temporarily colonize and continuously produce and release LEKTI (Lympho-epithelial Kazal-type-related inhibitor), a serine protease inhibitor encoded by the SPINK5 gene. In Netherton syndrome, mutations in SPINK5 lead to a deficiency of LEKTI, resulting in uncontrolled activity of kallikrein-related peptidases (KLKs) such as KLK5, KLK7, and KLK14. This excessive proteolysis causes premature exfoliation of the skin and severe barrier defects. By restoring LEKTI levels locally, RVB-001 aims to inhibit these proteases, reduce inflammation, and restore the integrity of the epidermal barrier. The FDA granted RVB-001 Rare Pediatric Disease Designation in 2022.

Targets

KLK14 (Kallikrein-related peptidase 14)KLK5 (Kallikrein-related peptidase 5)KLK7

Beyond the preview

Go deeper on RVB-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RVB-001.

Explore the full profile